Merck & Co., Inc. (MRK)
Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?
MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.
Why Is Merck Stock Surging?
Merck (MRK)'s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings exceeding expectations, the FDA's approval of Keytruda's new formulation, and an excellent upgrade from Wells Fargo, several factors contributed to this boost—let's delve into the main reasons for the rise.
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
Pharma Stock Pops on Wells Fargo Upgrade
Pharmaceutical stock Merck & Co (NYSE:MRK) is up 4% at $101.64 at last glance, after an upgrade from Wells Fargo to "overweight" from "equal weight," with a price-target hike to $125 from $90.
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript
Merck & Co., Inc. ( MRK ) Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Marjorie C. Green - Senior VP & Head of Late-Stage Oncology - Global Clinical Development Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Last day.
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Here's Why Merck (MRK) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Merck Has Many Bullish Attributes (Technical Analysis)
Merck presents a bullish investment case with strong valuation, improving grades, and a well-supported, growing dividend. MRK's technical setup is positive: price trades above its 30-week EMA, momentum indicators are bullish, and volume shows institutional accumulation. Since its May low, the company has outperformed the S&P 500, with relative strength now trending higher and above its 30-week EMA.
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of November
This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Dividend growth picked up from companies in the first half of November, with 6 companies announcing 10%+ increases, including ADP, Roper Technologies, Atmos, and Snap-on. Other notable companies expecting dividend hikes include Motorola Solutions, McCormick, and Raymond James, each with robust earnings trends.
